

Title (en)

IMMUNOMODULATORY HUMAN MHC CLASS II ANTIGEN-BINDING POLYPEPTIDES

Title (de)

ANTIGEN BINDENDE POLYPEPTIDE ZUR IMMUNMODULATION DES MENSCHLICHEN MHC KLASSE IIKOMPLEXES

Title (fr)

POLYPEPTIDES IMMUNOMODULATEURS SE LIANT A L'ANTIGENE HUMAIN MHC DE CLASSE II

Publication

EP 1303303 A4 20090610 (EN)

Application

EP 01937390 A 20010514

Priority

- EP 01937390 A 20010514
- EP 00110063 A 20000512
- US 0115626 W 20010514
- US 23876200 P 20001006

Abstract (en)

[origin: EP1156062A1] The present invention relates to human peptides/proteins comprising at least one antibody-based antigen-binding domain of human composition with a binding specificity for a human MHC class II antigen, wherein binding of said peptide/protein to said antigen expressed on the surface of a cell causes or leads to modulation of the immune system. The invention further relates to nucleic acids encoding said peptides/proteins, methods for production, immunosuppression, pharmaceutical and diagnostic compositions or kits comprising the peptides/proteins and uses of the peptides/proteins.

IPC 1-7

C07K 16/28; **A61K 39/395**; **A61K 48/00**; **G01N 33/53**; **A61P 37/00**

IPC 8 full level

A61K 38/00 (2006.01); **A61K 39/00** (2006.01); **A61K 39/395** (2006.01); **A61K 48/00** (2006.01); **A61P 1/00** (2006.01); **A61P 1/16** (2006.01); **A61P 1/18** (2006.01); **A61P 3/10** (2006.01); **A61P 13/12** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **A61P 21/04** (2006.01); **A61P 25/02** (2006.01); **A61P 29/00** (2006.01); **A61P 37/02** (2006.01); **A61P 37/06** (2006.01); **A61P 43/00** (2006.01); **C07K 16/28** (2006.01); **C12N 1/15** (2006.01); **C12N 1/19** (2006.01); **C12N 5/06** (2006.01); **C12N 5/07** (2010.01); **C12N 5/0783** (2010.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12P 21/02** (2006.01); **C12Q 1/02** (2006.01); **G01N 33/50** (2006.01); **G01N 33/53** (2006.01)

CPC (source: EP)

A61P 1/00 (2017.12); **A61P 1/16** (2017.12); **A61P 1/18** (2017.12); **A61P 3/10** (2017.12); **A61P 13/12** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 21/04** (2017.12); **A61P 25/02** (2017.12); **A61P 29/00** (2017.12); **A61P 37/00** (2017.12); **A61P 37/02** (2017.12); **A61P 37/06** (2017.12); **A61P 43/00** (2017.12); **C07K 16/28** (2013.01); **C07K 16/2833** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/21** (2013.01); **C07K 2317/34** (2013.01); **C07K 2317/55** (2013.01); **C07K 2317/565** (2013.01); **C07K 2317/622** (2013.01); **C07K 2317/73** (2013.01); **C07K 2317/76** (2013.01); **Y02A 50/30** (2017.12)

Citation (search report)

- [X] WO 9617874 A1 19960613 - HOFFMANN LA ROCHE [CH], et al
- [X] D. VIDOVIC ET AL.: "Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragments.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 25, no. 12, December 1995 (1995-12-01), Germany, pages 3349 - 3355, XP000564479
- [X] D. VIDOVIC ET AL.: "Selective apoptosis of neoplastic cells by the HLA-DR-specific monoclonal antibody.", CANCER LETTERS, vol. 128, 1998, New York, NY, USA, pages 127 - 135, XP002944554
- [A] H. VIKEN ET AL.: "Serologic subtyping of HLA-DR8 by means of the cytotoxic human monoclonal antibody 5643.", HUMAN IMMUNOLOGY, vol. 43, no. 3, July 1995 (1995-07-01), USA, pages 200 - 206, XP000939101
- [A] H. VIKEN ET AL.: "The cytotoxic HLA-DQ3 reactive human hybridoma antibody 4166 that may distinguish DQ7+8 from DQ9.", HUMAN IMMUNOLOGY, vol. 42, no. 4, 1995, USA, pages 281 - 288, XP002524443
- [A] R. EFROS ET AL.: "A human-human hybridoma secreting anti-HLA class II antibody.", THE JOURNAL OF IMMUNOLOGY, vol. 137, no. 5, 1 September 1986 (1986-09-01), Germany, pages 1599 - 1603, XP002524442
- [A] A. KNAPPIK ET AL.: "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.", JOURNAL OF MOLECULAR BIOLOGY, vol. 296, 2000, pages 57 - 86, XP004461525
- [T] Z. NAGY ET AL.: "Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.", NATURE MEDICINE, vol. 8, no. 8, August 2002 (2002-08-01), USA, pages 801 - 807, XP002432676
- See references of WO 0187338A1

Cited by

US10336820B2; US7521053B2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated extension state (EPC)

LT LV

DOCDB simple family (publication)

EP 1156062 A1 20011121; AU 2001263133 B2 20060810; AU 6313301 A 20011126; CA 2408513 A1 20011122; CN 100478029 C 20090415; CN 1460025 A 20031203; EP 1303303 A1 20030423; EP 1303303 A4 20090610; JP 2004500847 A 20040115; RU 2002129930 A 20040510; RU 2004121674 A 20060110; WO 0187338 A1 20011122

DOCDB simple family (application)

EP 00110063 A 20000512; AU 2001263133 A 20010514; AU 6313301 A 20010514; CA 2408513 A 20010514; CN 01809333 A 20010514; EP 01937390 A 20010514; JP 2001583805 A 20010514; RU 2002129930 A 20010514; RU 2004121674 A 20040714; US 0115626 W 20010514